1. Home
  2. SUPN vs LMAT Comparison

SUPN vs LMAT Comparison

Compare SUPN & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • LMAT
  • Stock Information
  • Founded
  • SUPN 2005
  • LMAT 1983
  • Country
  • SUPN United States
  • LMAT United States
  • Employees
  • SUPN N/A
  • LMAT N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • SUPN Health Care
  • LMAT Health Care
  • Exchange
  • SUPN Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • SUPN 1.9B
  • LMAT 2.0B
  • IPO Year
  • SUPN 2012
  • LMAT 2006
  • Fundamental
  • Price
  • SUPN $37.77
  • LMAT $102.57
  • Analyst Decision
  • SUPN Hold
  • LMAT Buy
  • Analyst Count
  • SUPN 1
  • LMAT 7
  • Target Price
  • SUPN $36.00
  • LMAT $92.83
  • AVG Volume (30 Days)
  • SUPN 393.7K
  • LMAT 144.5K
  • Earning Date
  • SUPN 11-04-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • SUPN N/A
  • LMAT 0.62%
  • EPS Growth
  • SUPN 130.79
  • LMAT 49.21
  • EPS
  • SUPN 1.07
  • LMAT 1.82
  • Revenue
  • SUPN $651,972,000.00
  • LMAT $213,029,000.00
  • Revenue This Year
  • SUPN $7.82
  • LMAT $16.04
  • Revenue Next Year
  • SUPN N/A
  • LMAT $9.62
  • P/E Ratio
  • SUPN $35.57
  • LMAT $56.33
  • Revenue Growth
  • SUPN 6.79
  • LMAT 14.81
  • 52 Week Low
  • SUPN $25.53
  • LMAT $50.42
  • 52 Week High
  • SUPN $39.37
  • LMAT $106.49
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 70.18
  • LMAT 66.91
  • Support Level
  • SUPN $35.87
  • LMAT $99.80
  • Resistance Level
  • SUPN $39.37
  • LMAT $106.49
  • Average True Range (ATR)
  • SUPN 1.54
  • LMAT 3.73
  • MACD
  • SUPN 0.28
  • LMAT 1.29
  • Stochastic Oscillator
  • SUPN 73.06
  • LMAT 82.02

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: